
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>To summarize and illuminate the recent findings regarding gastroduodenal mucosal defense mechanisms and the specific biomolecules involved in regulating this process, such as glucagon-like peptides (GLPs).There has been a growing interest in luminal nutrient chemosensing and its physiological effects throughout the digestive system. From the ingestion of food in the oral cavity to the processing and absorption of nutrients in the intestines, nutrient chemosensing receptors signal the production and release of numerous bioactive peptides from enteroendocrine cells, such as the proglucagon-derived peptides. There has been a major emphasis on two proglucagon-derived peptides, namely GLP-1 and GLP-2, due to their apparent beneficial effect on gut structure, function, and on metabolic processes. As an incretin, GLP-1 not only enhances the effect and release of insulin on pancreatic βcells but also has been implicated in having trophic effects on the intestinal epithelium. In addition, GLP-2, the other major proglucagon-derived peptide, has potent intestinotrophic effects, such as increasing the rate of mucosal stem cell proliferation, mucosal blood flow, and fluid absorption, as well as augmenting the rate of duodenal bicarbonate secretion to improve gastric mucosal health and longevity.Understanding the mechanisms underlying nutrient chemosensing and how it relates to GLP release can further elucidate how the gut functions in response to cellular changes and disturbances. Furthermore, a more in-depth comprehension of GLP release and its tissue-specific effects will help improve the utility of GLP-1 and GLP-2 receptor agonists in clinical settings. This, in turn, should help patients suffering from intestinal failure, malabsorption, and mucosal injury.
Gastrointestinal Diseases, 1.1 Normal biological development and functioning, Clinical Sciences, Glucagon-Like Peptides, Clinical sciences, gastric mucosal defense, Oral and gastrointestinal, trophic feeds, Underpinning research, Glucagon-Like Peptide 1, Glucagon-Like Peptide 2, Humans, Nutritional Physiological Phenomena, Intestinal Mucosa, Metabolic and endocrine, Nutrition, nutrient chemosensing, Clinical Trials as Topic, Biomedical and Clinical Sciences, Gastroenterology & Hepatology, glucagon-like peptides, free fatty acid receptors, gut taste receptors, Gastric Mucosa, Digestive Diseases
Gastrointestinal Diseases, 1.1 Normal biological development and functioning, Clinical Sciences, Glucagon-Like Peptides, Clinical sciences, gastric mucosal defense, Oral and gastrointestinal, trophic feeds, Underpinning research, Glucagon-Like Peptide 1, Glucagon-Like Peptide 2, Humans, Nutritional Physiological Phenomena, Intestinal Mucosa, Metabolic and endocrine, Nutrition, nutrient chemosensing, Clinical Trials as Topic, Biomedical and Clinical Sciences, Gastroenterology & Hepatology, glucagon-like peptides, free fatty acid receptors, gut taste receptors, Gastric Mucosa, Digestive Diseases
| citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 36 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
